http://jcps.bjmu.edu.cn

中国药学(英文版) ›› 2016, Vol. 25 ›› Issue (11): 855-858.

• 【其它】 • 上一篇    

Information from US FDA

http://www.fda.gov   

  1. http://www.fda.gov
  • 收稿日期:2016-11-10 修回日期:2016-11-13 出版日期:2016-11-26 发布日期:2016-11-16

Information from US FDA

http://www.fda.gov   

  1. http://www.fda.gov
  • Received:2016-11-10 Revised:2016-11-13 Online:2016-11-26 Published:2016-11-16

摘要:  

Here at FDA, we work diligently to be part of our nation’s solution to the opioid abuse epidemic. While there is no single solution to this complex problem, we continue to encourage efforts to develop new opioid formulations with abuse-deterrent properties that make it harder to abuse these powerful medications.

Knowing there are some 100 million Americans with significant pain each year, we need to help ensure that patients in need continue to have appropriate access to pain medications, including opioids. At the same time we must work to ensure that these powerful medications are used as safely as possible.

 

Abstract:  

Here at FDA, we work diligently to be part of our nation’s solution to the opioid abuse epidemic. While there is no single solution to this complex problem, we continue to encourage efforts to develop new opioid formulations with abuse-deterrent properties that make it harder to abuse these powerful medications.

Knowing there are some 100 million Americans with significant pain each year, we need to help ensure that patients in need continue to have appropriate access to pain medications, including opioids. At the same time we must work to ensure that these powerful medications are used as safely as possible.

 

Supporting: